A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Field-proven COVID-19 Telemedicine Solution for Hospitals

Deployable Within 48 Hours: Launched by Datos Leveraging Accumulated Experience in Monitoring Coronavirus Symptoms, Israeli Telehealth Company Releases Solution to Avoid Low-risk Patients Overwhelming Hospitals

As COVID-19 continues to spread, hospitals are expecting a surge in visitors to clinics and emergency rooms, which would result in a challenging additional burden on an already overstretched medical system.

Datos’s solution, easily implemented within 48 hours, is specifically designed to support hospitals across the world to mitigate such a situation by helping to keep suspected corona patients, and those infected but not requiring hospitalization, at home while still providing them with optimal care.

Hospitals and HMOs will be able to quickly deploy a robust and scalable COVID-19 telemedicine solution tailored to provide virtual services, including online symptom-checking tools and remote consultations with doctors, while simultaneously minimizing direct contact with those infected with the coronavirus.

The Datos COVID-19-specific telemedicine package is already in use at Sheba Medical Center, Israel’s largest hospital, and has begun implementations in U.S. hospital systems.

“Datos is providing an important solution for the US health care system to monitor COVID-19 remotely, easing the demand for inpatient-based monitoring at hospitals,” said Uri Bettesh, CEO of Datos Health. “The first solution of its kind, we are able to deploy it within 48 hours. It requires no additional resources as it seamlessly integrates with care teams’ existing workflows, providing crucial insights into patients being monitored outside the hospital at a fraction of the cost. Treating patients – who do not require hospitalization – out of emergency rooms could ensure that key resources are available for the most serious cases.”

The Datos COVID-19 solution offers:

  • For care teams, a fully configured COVID-19 dashboard that includes an overall view of all patients sorted according to the severity of coronavirus symptoms, the delivery of daily symptom checkout surveys, the seamless launch of virtual visits via video calls (including via text message, without requiring the Datos app), data-driven reminders (to measure temperature and complete surveys), messages and content.
  • For patients, a user-friendly mobile app (available on iOS and Android) for home hospitalized patients to manually enter their relevant vitals, including body temperature, BP and saturation. Patients will be asked to respond to two types of coronavirus surveys, an initial assessment followed by daily symptom status updates, sent automatically and then scored and correlated with monitored vitals to yield timely reminders, personalized messages and virtual doctor visits via video calls.

The solution additionally provides health systems with a private, HIPAA compliant, cloud-based interface of the Datos platform anywhere in the world. Optional extras include services delivered via a text message with links to web pages for reporting vitals management, survey distribution and video calls.

SourceDatos
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy